[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633313":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":20,"responsibleParty":35,"collaborators":37,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":20,"enrollmentInfo":49,"targetDuration":20,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":70,"whyStopped":20,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":20},{"fullName":5,"class":6},"Duke University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Active TMS","EXPERIMENTAL","Participants receive TMS over 4 consecutive days (20 sessions total).",[13],"Device: Transcranial Magnetic Stimulation (TMS)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Transcranial Magnetic Stimulation (TMS)","TMS protocol delivered via MagPro X100 stimulator with figure-8 coil targeting prefrontal cortex.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Katherine T Martucci, PhD","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Martucci Lab Clinical Research Specialist","CONTACT","919-684-3161","ChronicPainResearch@duke.edu",{"name":32,"role":28,"phone":33,"phoneExt":20,"email":34},"Darius Williams","919-684-2758","ladarius.williams@duke.edu",{"type":36,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[38],{"name":39,"class":6},"American Fibromyalgia Syndrome Association","100633313","pain--reward-neuromodulation-of-cns-circuits-100633313",false,"NCT07525063","Pain & Reward Neuromodulation of CNS Circuits","PRANCIR","Inclusions:\n\n1. Female and ages 18 +\n2. Ability to read\u002Funderstand English and give consent to participate\n3. Physician diagnosis \\& confirmation of primary fibromyalgia syndrome\n4. Verbal agreement to maintain dose of prescribed medication (if any) constant throughout the study, except exclusion medication and except if there is a medical emergency requiring changes in medication\n5. If enrolled in psychotherapy, verbal agreement to maintain (not change or stop) the psychotherapy during the study\n6. Absence of use of opioid medications (during the previous 90 days, and no greater than a 30-day period during lifetime)\n\nExclusions:\n\n1. limited ability to participate fully in behavioral tasks, longitudinal follow-up (e.g., plans to move out-of-state within 3 months)\n2. MRI contraindication (e.g., metal implants, claustrophobia, pregnant or planning to become pregnant)\n3. any factors that at the discretion of the investigators would adversely affect the participant or the integrity of the study (e.g., ongoing legal action or disability claim regarding pain, uncontrolled psychiatric disorder, head\u002Fneck injury, use of certain medications)\n4. male \\*\n\nTMS-Specific Exclusions:\n\n1\\. TMS contraindication (e.g., history of seizures, medications contraindicated for risks\u002Fefficacy of TMS procedures)\n\n1. current hypomania,\n2. meets diagnostic criteria for current psychotic disorder, or psychotic features,\n3. meets diagnostic criteria for Bipolar I disorder,\n4. meets diagnostic criteria for current alcohol or substance use disorder (moderate and high severity)\n5. current uncontrolled anorexia or other condition requiring hospitalization,\n6. current serious medical illness, including current severe migraine headaches,\n7. changed psychotropic medications in the prior 2 months, or plans to change medication during the study,\n8. history of seizure except those therapeutically induced by ECT (childhood febrile seizures are acceptable and these subjects may be included in the study), history of epilepsy in self or first degree relatives, stroke, brain surgery, head injury, cranial metal implants, known structural brain lesion, devices that may be affected by TMS (pacemaker, medication pump, cochlear implant, implanted brain stimulator),\n9. conditions associated with increased intracranial pressure, space occupying brain lesion, transient ischemic attack, cerebral aneurysm, dementia, Parkinson's or Huntington's disease, multiple sclerosis,\n10. use of investigational drug or devices within 4 weeks of screening,\n11. cochlear implants,\n12. pregnancy\n\n    * Only females will be enrolled in this study because it focuses on patients who have fibromyalgia which is more prevalent (both diagnosed and self-reported) in females.\n\nDue to the contributions of hormones to the conditions under study in this project, female eligibility in this study will be defined as an individual who is female sex at birth and currently female sex","FEMALE","18 Years",{"count":50,"type":51},30,"ESTIMATED","INTERVENTIONAL",[54],"NA","This pilot feasibility study aims to evaluate transcranial magnetic stimulation (TMS) targeting the prefrontal cortex in patients with fibromyalgia syndrome (FMS). The study will assess preliminary efficacy and mechanisms of central nervous system changes using neuroimaging, behavioral tasks, sensory testing, and neuroimmune markers. Participants will undergo MRI scans, multi-day TMS sessions, and complete questionnaires. The goal is to generate pilot data for future trials on neuromodulation for chronic pain.",[57,58,59],"Fibromyalgia Syndrome","Fibromyalgia","Chronic Pain and Fatigue",[58,61,62,63,64,65,66,67,68,57,69],"Transcranial Magnetic Stimulation","Neuromodulation","fatigue","cognitive issues","fibro fog","brain fog","trouble sleeping","AFSA","pain","NOT_YET_RECRUITING","2026-06-01",{"date":73,"type":74},"2026-06-03","ACTUAL",{"date":76,"type":51},"2026-07",{"date":78,"type":51},"2027-06",{"name":5,"class":6}]